Covid-19 vaccines

Cathie Wood-led Ark Invest on Friday snapped up yet more shares in Pinduoduo Inc (NASDAQ: PDD), its fourth straight-session buy in the agriculture-focused tech platform. Ark Invest bought 62,767 shares — estimated to be worth $5.94 million — in Pinduoduo via the Ark Fintech Innovation...

Cathie Wood-led Ark Invest on Wednesday trimmed all of its exposure to Netflix Inc (NASDAQ: NFLX) in one of the two active exchange-traded funds that own shares in the streaming video on-demand service.  The popular money managing firm sold 192 shares —estimated to be...

More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia reported Wednesday. What Happened: Nearly 1.6 million doses were put out of use in Japan, as per the country’s...

Pfizer Inc. (NYSE: PFE) CEO said the company is working on a specialized vaccine targeting the highly contagious delta variant of COVID-19. What Happened: “We are making a specialized vaccine for Delta. I am almost certain that we will not need it because the booster shot of the current...

Heading into a new trading week, Pfizer Inc. (NYSE: PFE), Alibaba Group Holding Limited (NYSE: BABA), Nvidia Corp. (NASDAQ: NVDA) and Moderna Inc. (NASDAQ: MRNA) are among the stocks seeing the highest interest on Reddit’s r/WallStreetBets forum. What Happened: Pfizer has emerged as the most-...

There has been some exciting news from the biotech, cryptocurrency and corporate sectors that investors may have missed over the weekend. Here is a quick look at the top five stories. Bitcoin Crosses $50,000 Mark: Bitcoin (CRYPTO: BTC) reclaimed the crucial $50,000 level for the first time...

The U.S. Food and Drug Administration is expected to authorize on Thursday a third dose of the Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) and Moderna Inc. (NASDAQ: MRNA) COVID-19 vaccines for certain people with weakened immune systems, the New York Times reported. What Happened: The...

Novavax, Inc (NASDAQ: NVAX) shares slipped nearly 10% in the after-hours trading on Thursday. What’s Moving? The biotechnology company’s shares crashed 9.79% to $213.07 in the after-hours session on Thursday after closing 5.54% higher at $236.20. The fall in the shares came after the...

The COVID-19 pandemic caused major changes to sports schedules over the last year and a half. The National Football League outlined new procedures for the upcoming 2021 season that could cost players and teams if an outbreak occurs. What Happened: A league-wide memo sent from NFL commissioner Roger...

CNBC host Jim Cramer said that Moderna Inc.’s (NASDAQ: MRNA) stock is “too high at this point” and the biotechnology company’s crucial test is whether it can offer personalized cancer vaccines in time to offset the decline in COVID-19 vaccine sales. What Happened: Cramer...

Shares of Johnson & Johnson (NYSE: JNJ) rose 0.7% in the regular trading session on Thursday and were trading slightly higher in the market session on Friday. What Happened: Johnson & Jonson said late Thursday that its single-shot COVID-19 vaccine showed strong promise against the fast-...

Ocugen Inc (NASDAQ: OCGN) shares are trading 1.6% higher in the pre-market session on Wednesday amid high social media interest. The company's shares had closed nearly 2% lower at $8.46 in the regular session, the day prior. Ocugen is the top-trending stock on Stocktwits at press time and also...

Shares of COVID-19 vaccine companies Moderna Inc (NASDAQ: MRNA), Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) are moving sharply lower Wednesday. What Happened: Administering of mRNA vaccines, the class of vaccines developed by Moderna and Pfizer-BioNTech, resulted in...

CureVac N.V.’s (NASDAQ: CVAC) Chief Financial Officer Pierre Kemula is optimistic its COVID-19 vaccine could still be offered to certain age groups or as a booster, the Financial Times reported on Thursday. What Happened: Kemula told FT the German vaccine developer is still hopeful the...

Shares of Ocugen Inc. (NASDAQ: OCGN), India-based Bharat Biotech’s U.S. partner for COVID-19 vaccine Covaxin, fell 3.7% in Wednesday’s regular trading session. What Happened: Ocugen said late Wednesday it plans to submit an Emergency Use Authorization (EUA) application for Covaxin to...